| dc.contributor.author | Hierro Bujalance, Carmen | |
| dc.contributor.author | García Alloza, Mónica | |
| dc.contributor.other | Biomedicina, Biotecnología y Salud Pública | es_ES |
| dc.date.accessioned | 2024-05-02T12:14:12Z | |
| dc.date.available | 2024-05-02T12:14:12Z | |
| dc.date.issued | 2024 | |
| dc.identifier.issn | 1876-7958 | |
| dc.identifier.issn | 1673-5374 | |
| dc.identifier.uri | http://hdl.handle.net/10498/32070 | |
| dc.description.abstract | Alzheimer’s disease (AD) and type 2 diabetes
(T2D): More than 55 million people suffer from
dementia, and it is expected that over 150 million
people will suffer from this disease by 2050. AD
is the most common type of dementia and while
aging remains the main risk factor to suffer it,
previous studies have also shown that metabolic
disorders, and T2D specifically, are also major
contributors (Wang et al., 2012). The prevalence
of diabetes has reached 537 million people
worldwide and these figures are expected to keep
rising (Ahmad et al., 2022). All things considered,
both diseases are a great challenge for health. | es_ES |
| dc.format | application/pdf | es_ES |
| dc.language.iso | eng | es_ES |
| dc.publisher | Wolters Kluwer Medknow Publications | es_ES |
| dc.rights | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
| dc.source | Neural Regeneration Research - 2024, Vol. 19 n. 6, pp. 1189 - 1190 | es_ES |
| dc.title | Empagliflozin reduces brain pathology in Alzheimer’s disease and type 2 diabetes | es_ES |
| dc.type | journal article | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.identifier.doi | 10.4103/1673-5374.385865 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-115499RB-I00/ES/COMPLICACIONES TEMPRANAS EN LA ENFERMEDAD DE ALZHEIMER Y EN DIABETES MELLITUS TIPO 2: IMPLICACIONES FARMACOLOGICAS/ | es_ES |
| dc.type.hasVersion | VoR | es_ES |